Madrigal Pharmaceuticals Reports Q3 Revenue of $431.27 Million, EPS of $1.83
Third-quarter revenue rose 50.1% year over year to $431.27 million. Net income was $55.44 million, versus a year-earlier net loss of $114.19 million; diluted EPS was $1.83 versus a loss of $4.01.
Madrigal Pharmaceuticals reported third-quarter 2026 revenue of $431.27 million, up 50.1% from the prior-year quarter, and net income of $55.44 million compared with a net loss of $114.19 million. Diluted EPS was $1.83 versus a loss of $4.01 a year earlier.Financial Highlights¹ Reported as “Product…